natgillin/translations-raw huggingface dataset:
It is unknown whether saxagliptin and dapagliflozin and/or its metabolites are excreted in human milk. 
Ni znano, ali se saksagliptin, dapagliflozin in/ali njuni presnovki pri človeku izločajo v materino mleko.
Dapagliflozin is a highly potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2). 
Dapagliflozin je zelo močan (Ki: 0,55 nM), selektiven in reverzibilen zaviralec natrij-glukoznega soprenašalca 2 (SGLT2).
Consequently, low-weight patients may have somewhat increased exposure and patients with high-weight somewhat decreased exposure. 
Zato je lahko izpostavljenost pri bolnikih z majhno telesno maso nekoliko večja in pri bolnikih z veliko telesno maso nekoliko manjša.
Adverse reactions were reported in ≥ 2 % of subjects with either mono-component and ≥ 1 % more than placebo, but not in the pooled analysis. 
Neželeni učinki, o katerih so poročali pri ≥ 2 % preiskovancev s katero koli od teh učinkovin in pri ≥ 1 % več kot s placebom, ne pa v kumulativni analizi.
No episodes of major hypoglycaemia were reported, and no subject discontinued the study treatment due to hypoglycaemia. 
Zabeležili niso nobenih hudih hipoglikemij in noben bolnik ni zaradi hipoglikemije prenehal zdravljenja s tem zdravilom.
Considering the lack of tumour findings in non-clinical studies as well as the short latency between first drug exposure and tumour diagnosis, a causal relationship is considered unlikely. 
Ker ni izsledkov o tumorjih v predkliničnih študijah in ker je latenca med prvo izpostavljenostjo zdravilu in diagnozo tumorja kratka, vzročna povezava ni verjetna.
In the SAVOR trial, a small increase in the rate for hospitalisation for heart failure was observed in the saxagliptin-treated patients compared to placebo, although a causal relationship has not been established (see section 5.1). 
V preskušanju SAVOR so med bolniki, zdravljenimi s saksagliptinom, opažali majhen porast deleža sprejemov v bolnišnico zaradi srčnega popuščanja v primerjavi z bolniki, ki so prejemali placebo, toda vzročne povezave niso ugotovili (glejte poglavje 5.1).
Dapagliflozin: There is no clinically meaningful increase in exposure based on age alone in subjects up to 70 years old. 
Dapagliflozin: Bolniki v starosti do 70 let zgolj zaradi starosti nimajo klinično pomembno večje izpostavljenosti.
- Dehydration, (loss of too much fluid from your body), seen uncommonly (may affect up to 1 in 100 people). 
- Dehidracija (prekomerna izguba tekočine iz telesa) je občasna (pojavi se lahko pri največ 1 od 100 bolnikov).
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl peptidase-4 (DPP-4) inhibitor or to any sodium-glucose co-transporter 2 (SGLT2) inhibitor (see sections 4.4, 4.8 and 6.1). 
Preobčutljivost na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1, ali anamneza resne preobčutljivostne reakcije, vključno z anafilaktično reakcijo, anafilaktičnim šokom ali angioedemom, na kateri koli zaviralec dipeptidilpeptidaze-4 (DPP-4) ali kateri koli zaviralec natrij-glukoznega soprenašalca 2 (SGLT2 - sodium-glucose co-transporter 2) (glejte poglavja 4.4, 4.8 in 6.1).
Dapagliflozin dosed to maternal rats from gestation day 6 through postnatal day 21, and pups were indirectly exposed in utero and throughout lactation. 
Dapagliflozin, je bil uporabljen pri podganjih samicah-materah od 6. do 21. postnatalnega dneva in mladiči so bili posredno izpostavljeni in utero ter med obdobjem dojenja.
The adverse reactions are listed by system organ class (SOC) and frequency. 
Neželeni učinki so našteti po organskem sistemu in pogostnosti.
- Pancreatitis, seen uncommonly (may affect up to 1 in 100 people): severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas. 
- Pankreatitis je občasen (pojavi se lahko pri največ 1 od 100 bolnikov): huda in nenehna bolečina v trebuhu, ki se lahko širi v hrbet, pa tudi slabost (navzea) ali bruhanje, ker je to lahko znak vnetja trebušne slinavke (pankreatitisa).
In male and female rats, dapagliflozin showed no effects on fertility at any dose tested. 
Pri podganjih samcih in samicah dapagliflozin v nobenem testiranem odmerku ni vplival na plodnost.
No episodes of major hypoglycaemia were reported, and no subject discontinued the study treatment due to hypoglycaemia (see sections 4.4 and 
O primerih hude hipoglikemije niso poročali in noben bolnik ni prenehal uporabljati raziskovanega zdravila zaradi hipoglikemije (glejte poglavji 4.4 in 4.5).
The degree of renal impairment did not affect the Cmax of saxagliptin or its major metabolite. 
Stopnja okvare ledvic ni vplivala na Cmax saksagliptina ali njegovega glavnega presnovka.
Dapagliflozin: The metabolism of dapagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyltransferase 1A9 (UGT1A9). 
Dapagliflozin: Presnova dapagliflozina poteka predvsem z glukuronidno konjugacijo z UDP-glukuronoziltransferazo 1A9 (UGT1A9).
The adverse reactions of Qtern are presented in table 1 based on the summarized data from the saxagliptin/dapagliflozin combination clinical trials pooled safety data. 
Neželeni učinki zdravila Qtern so prikazani v preglednici 1 na podlagi povzetka podatkov iz kumulativnih varnostnih podatkov kliničnih preskušanj kombinacije saksagliptin/dapagliflozin.
Additionally, urinary tract infections were frequently reported in saxagliptin and dapagliflozin clinical programmes. 
Poleg tega so o okužbah sečil pogosto poročali v kliničnih programih saksagliptina in dapagliflozina
In patients where DKA is suspected or diagnosed, treatment with Qtern should be discontinued immediately. 
V primeru suma na DKA ali potrjene DKA je treba zdravljenje z zdravilom Qtern takoj prekiniti.
Mechanism of action for Qtern 
Mehanizem delovanja zdravila Qtern
Dapagliflozin blocks reabsorption of filtered glucose from the S1 segment of the renal tubule, effectively lowering blood glucose in a glucose dependent and insulin-independent manner. 
Dapagliflozin prepreči reabsorpcijo filtrirane glukoze iz segmenta S1 ledvičnih tubulov in učinkovito zniža glukozo v krvi v odvisnosti od glukoze in neodvisno od insulina.
Necrotising fasciitis of the perineum (Fournier's gangrene) Post-marketing cases of necrotising fasciitis of the perineum (also known as Fournier's gangrene) have been reported in female and male patients taking SGLT2 inhibitors. 
Nekrotizirajoči fasciitis presredka (Fournierjeva gangrena) Po začetku trženja so poročali o primerih nekrotizirajočega fasciitisa presredka (znan tudi kot Fournierjeva gangrena) pri bolnikih in bolnicah, ki so jemali zaviralce SGLT2.
The safety and efficacy of the 5 mg saxagliptin/10 mg dapagliflozin fixed-dose combination was evaluated in three phase 3, randomised, double-blind, active/placebo-controlled clinical trials in 1169 adult subjects with type 2 diabetes mellitus. 
Varnost in učinkovitost fiksne kombinacije 5 mg saksagliptina/10 mg dapagliflozina so proučili v treh randomiziranih, dvojno slepih, z aktivno učinkovino/placebom kontroliranih kliničnih preskušanjih 3. faze pri 1169 odraslih s sladkorno boleznijo tipa 2.
You are advised to follow the recommendations for skin care that you are given by your doctor or nurse. 
Upoštevajte priporočila za nego kože, ki vam jih je dal zdravnik ali medicinska sestra.
Therapeutic experience with Qtern in patients 65 years and older is limited, and very limited in patients 75 years and older. 
Terapevtskih izkušenj z zdravilom Qtern pri bolnikih, starih 65 let ali več, je malo, pri bolnikih, starih 75 let ali več, pa zelo malo.
- film-coating: polyvinyl alcohol (E1203), macrogol 3350, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172), red iron oxide (E172). 
- Filmska obloga: polivinilalkohol (E1203), makrogol 3350, titanov dioksid (E171), smukec (E553b), rumeni železov oksid (E172), rdeči železov oksid (E172).
It should also not be used in patients with end-stage renal disease (ESRD) (see section 4.4, 4.8, and 5.2). 
Prav tako se ga ne sme uporabljati pri bolnikih s končno odpovedjo ledvic (glejte poglavja 4.4, 4.8, in 5.2).
Therapeutic experience in patients 65 years and older is limited, and very limited in patients 75 years and older. 
Terapevtskih izkušenj pri bolnikih, starih 65 let ali več, je malo, pri bolnikih, starih 75 let ali več pa zelo malo.
After a mean follow up of 2 years, the trial met its primary safety endpoint demonstrating saxagliptin does not increase the cardiovascular risk in patients with type 2 diabetes compared to placebo when added to current background therapy. 
Po povprečno 2-letnem spremljanju je preskušanje doseglo svoj primarni opazovani dogodek varnosti in je dokazalo, da saksagliptin, dodan trenutnemu osnovnemu zdravljenju, v primerjavi s placebom pri bolnikih s sladkorno boleznijo tipa 2 ne poveča srčno-žilnega tveganja.
The safety profile of saxagliptin added to dapagliflozin plus metformin in the long-term treatment period was consistent with that previously observed in the clinical trial experience for the concomitant therapy study and that observed in the 24-week treatment period in this study. 
Varnostne značilnosti saksagliptina, dodanega dapagliflozinu in metforminu med dolgoročnim obdobjem zdravljenja, so se skladale z značilnostmi, predhodno ugotovljenimi v študiji sočasnega zdravljenja ter opaženimi v 24-tedenskem obdobju te študije.
Urine tests Because of how Qtern works, your urine will test positive for sugar while you are on this medicine. 
Zaradi načina delovanja zdravila Qtern boste imeli med zdravljenjem s tem zdravilom pozitiven izvid preiskav urina za prisotnost sladkorja.
The safety profile of the combined use of saxagliptin plus dapagliflozin in these trials for up to 52 weeks was comparable to the safety profiles for the mono-components. 
Varnostne značilnosti kombinirane uporabe saksagliptina in dapagliflozina v teh preskušanjih do 52 tednov so bile podobne varnostnim značilnostim posameznih učinkovin.
For patients receiving Qtern, in case of intercurrent conditions that may lead to volume depletion, careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended. 
Če se med zdravljenjem z zdravilom Qtern pojavijo bolezni, ki lahko povzročijo zmanjšanje volumna, je bolnikom priporočljivo skrbno kontrolirati volumsko stanje (npr. s kliničnim pregledom, meritvami krvnega tlaka, laboratorijskimi preiskavami, vključno s hematokritom).
Dyslipidaemia includes the following preferred terms: dyslipidaemia, hyperlipidaemia, hypercholesterolaemia, and hypertriglyceridaemia. 
Dislipidemija obsega naslednje prednostne izraze: dislipidemija, hiperlipidemija, hiperholesterolemija in hipertrigliceridemija.
The following reflects the pharmacokinetic properties of Qtern unless stated that the presented data are from administration of saxagliptin or dapagliflozin. 
V nadaljevanju so prikazane farmakokinetične lastnosti zdravila Qtern, razen kjer je navedeno, da prikazani podatki izvirajo iz uporabe saksagliptina ali dapagliflozina.
Another secondary endpoint, all-cause mortality, occurred at a rate of 5.1 % in the saxagliptin group and 4.6 % in the placebo group. 
Drug sekundarni opazovani dogodek, umrljivost zaradi vseh vzrokov, se je v skupini s saksagliptinom pojavil v 5,1 % in v skupini s placebom v 4,6 % (glejte preglednico 5).
There is no experience in clinical trials with dapagliflozin in NYHA class III-IV. 
Iz kliničnih preskušanj dapagliflozina ni izkušenj v razredih III. in IV. po NYHA.
Geometric mean steady-state dapagliflozin Cmax and AUCτ values following once daily 10 mg doses of dapagliflozin were 158 ng/ml and 628 ng h/ml, respectively. 
Geometrična sredina Cmax in AUCτ dapagliflozina v stanju dinamičnega ravnovesja po odmerkih 10 mg enkrat na dan sta bili 158 ng/ml in 628 ng h/ml.
If any of the above apply to you (or if you are not sure), talk to your doctor before taking Qtern. 
Če kaj od naštetega velja za vas (ali če niste prepričani), se posvetujte z zdravnikom, preden vzamete zdravilo Qtern.
Serum creatinine was further evaluated in those patients with events related to decreased renal function, and most observed increases in creatinine were ≤ 0.5 mg/dl from baseline. 
Pri bolnikih, ki so imeli učinke, povezane z zmanjšanim delovanjem ledvic, so nadalje spremljali kreatinin v serumu in večina opaženih zvišanj kreatinina je bila ≤ 0,5 mg/dl od izhodišča.
- Necrotising fasciitis of the perineum or Fournier's gangrene, a serious soft tissue infection of the genitals or the area between the genitals and the anus. 
- Nekrotizirajoči fasciitis presredka ali Fournierjeva gangrena, resna okužba mehkega tkiva spolovil ali predela med spolovili in zadnjikom.
Saxagliptin: Saxagliptin was rapidly absorbed after oral administration in the fasted state, with maximum plasma concentrations (Cmax) of saxagliptin and its major metabolite attained within 2 and 4 hours (Tmax), respectively. 
Saksagliptin: Saksagliptin se je po peroralni uporabi na tešče hitro absorbiral; najvišjo koncentracijo v plazmi (Cmax) je dosegel v 2 urah, njegov glavni presnovek pa v 4 urah (tmax).
Saxagliptin: The in vitro protein binding of saxagliptin and its major metabolite in human serum is negligible. 
Saksagliptin: Vezava saksagliptina in njegovega glavnega presnovka na beljakovine v človeškem serumu je in vitro zanemarljiva.
- printing ink: shellac, indigo carmine aluminium lake (E132). 
- črnilo za napis: šelak, indigotin (E132).
Cardiovascular death, MI and stroke were observed with a hazard ratio of 0.77 (95 % CI: 0.54, 1.10). 
Srčno-žilno smrt, miokardni infarkt in možgansko kap so zabeležili z razmerjem ogroženosti 0,77 (95 % IZ: 0,54, 1,10).
In studies of embryo-foetal development in rabbits, dapagliflozin caused neither maternal nor developmental toxicities at any dose tested; the highest dose tested corresponded to a systemic exposure 1191 times the MRHD. 
V študijah embrio-fetalnega razvoja pri kuncih dapagliflozin ni v nobenem od testiranih odmerkov povzročil ne maternalnih ne razvojnih toksičnih učinkov; največji testirani odmerek je ustrezal sistemski izpostavljenosti, 1191-krat večji od tiste pri največjem priporočenem odmerku za človeka).
Saxagliptin has effects on fertility in male and female rats at high doses producing overt signs of toxicity. 
Saksagliptin vpliva na plodnost podganjih samcev in samic v velikih odmerkih, ki povzročijo očitne znake toksičnosti.
Dapagliflozin: In the 21-study active- and placebo-controlled pool, the overall proportion of subjects with malignant or unspecified tumours was similar between those treated with dapagliflozin (1.50 %) and placebo/comparator (1.50 %), and there was no carcinogenicity or mutagenicity signal in animal data (see section 5.3). 
Dapagliflozin: V kumulativni analizi 21 z aktivno učinkovino in placebom kontroliranih študij je bil celotni delež oseb z malignimi ali neopredeljenimi tumorji med bolniki, zdravljenimi z dapagliflozinom (1,50 %) in bolniki, zdravljenimi s placebom/primerjalnim zdravilom (1,50 %) podoben, pa tudi na živalih dobljeni podatki niso pokazali kancerogenosti ali mutagenosti (glejte poglavje 5.3).
There were no clinically relevant differences observed in saxagliptin pharmacokinetics between males and females. 
Med moškimi in ženskami niso opažali klinično pomembnih razlik v farmakokinetiki saksagliptina.
The formation of dapagliflozin 3-O-glucuronide is mediated by UGT1A9, an enzyme present in the liver and kidney, and CYP-mediated metabolism was a minor clearance pathway in humans. 
Nastajanje dapagliflozin-3-O-glukuronida poteka z encimom UGT1A9, ki je prisoten v jetrih in ledvicah; presnova s sistemom CYP je pri človeku manj pomembna pot očistka.
Qtern contains lactose (milk sugar). 
Zdravilo Qtern vsebuje laktozo (mlečni sladkor).
There are no data from the use of saxagliptin and dapagliflozin in pregnant women. 
Podatkov o uporabi saksagliptina in dapagliflozina pri nosečnicah ni.
Upper respiratory tract infection includes the following preferred terms: nasopharyngitis, influenza, upper respiratory tract infection, pharyngitis, rhinitis, sinusitis, pharyngitis bacterial, tonsillitis, acute tonsillitis, laryngitis, viral pharyngitis, and viral upper respiratory tract infection. 
Okužba zgornjih dihal vključuje naslednje prednostne izraze: nazofaringitis, gripa, okužba zgornjih dihal, faringitis, rinitis, sinuzitis, bakterijski faringitis, tonzilitis, akutni tonzilitis, laringitis, virusni faringitis in virusna okužba zgornjih dihal
SAVOR was a CV outcome trial in 16,492 patients with HbA1c ≥ 6.5 % and < 12 % (12,959 with established CV disease; 3533 with multiple risk factors only) who were randomised to saxagliptin (n=8280) or placebo (n=8212) added to regional standards of care for HbA1c and CV risk factors. 
Študija SAVOR je bila preskušanje srčno-žilnih izidov pri 16.492 bolnikih s HbA1c ≥ 6,5 % in < 12 % (12.959 z ugotovljeno srčno-žilno boleznijo in 3.533 takšnih, ki so imeli le več dejavnikov tveganja), randomiziranih na saksagliptin (n = 8.280) ali placebo (n = 8.212), dodan regionalnemu standardnemu zdravljenju glede HbA1c in srčno-žilnih dejavnikov tveganja.
- if you often get infections of the urinary tract or have a serious infection of the urinary tract, including urosepsis or pyelonephritis, which can cause fever and/or chills, burning sensation when passing water (urinating), blood in urine, pain in your back or side. 
- če imate pogosto okužbe sečil, ali če imate hudo okužbo sečil, vključno z urosepso ali pielonefritisom, ki lahko povzročijo zvišano telesno temperaturo in/ali mrzlico, pekoč občutek pri uriniranju, kri v urinu in bolečine v ledjih ali hrbtu.
If a patient presents with severe joint pain, continuation of therapy should be individually assessed. 
Če se pojavijo hude bolečine v sklepih, je treba pri vsakem bolniku posebej pretehtati, ali naj še naprej jemlje zdravilo.
Available pharmacodynamic/toxicological data in animals have shown excretion of dapagliflozin/metabolites in milk, as well as pharmacologically-mediated effects in breast-feeding offspring (see section 5.3). 
Farmakodinamični in toksikološki podatki za živali, ki so na voljo, kažejo na izločanje dapagliflozina oz. njegovih presnovkov v mleko ter farmakološke učinke pri dojenih mladičih (glejte poglavje 5.3).
Direct administration of dapagliflozin to weanling juvenile rats and indirect exposure during late pregnancy (corresponding to the second and third trimesters of pregnancy with respect to human renal maturation) and lactation are each associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny. 
Neposredna uporaba dapagliflozina pri nedavno odstavljenih podganjih mladičih in posredna izpostavljenost med pozno brejostjo (to ustreza drugemu in tretjemu trimesečju nosečnosti glede na dozorevanje ledvic pri človeku) in obdobjem dojenja sta bili povezani z večjo pojavnostjo in/ali izrazitostjo razširitev ledvičnega meha in tubulov pri potomstvu.
This medicinal product should not be used in patients with moderate to severe renal impairment (patients with creatinine clearance [CrCl] < 60 ml/min or estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m2, see sections 4.4, 4.8, 5.1 and 5.2). 
Tega zdravila se ne sme uporabljati pri bolnikih z zmerno do hudo okvaro ledvic (očistek kreatinina < 60 ml/min ali ocenjena hitrost glomerularne filtracije [eGFR - estimated glomerular filtration rate] < 60 ml/min/1,73 m2, glejte poglavja 4.4, 4.8, 5.1 in 5.2).
In rats, dapagliflozin was neither embryolethal nor teratogenic at exposures up to 1441 times the human values at the MRHD. 
Pri podganah dapagliflozin ni bil ne embrioletalen ne teratogen pri izpostavljenostih, ki so bile do 1441-krat večje od vrednosti pri človeku med uporabo največjega priporočenega odmerka za človeka.
- Diabetic ketoacidosis, seen rarely (may affect up to 1 in 1,000 people) These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions): - increased levels of “ketone bodies” in your urine or blood - rapid weight loss - feeling sick or being sick - stomach pain - excessive thirst - fast and deep breathing - confusion - unusual sleepiness or tiredness - a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat. 
- Diabetična ketoacidoza je redka (lahko se pojavi pri največ 1 od 1.000 bolnikov) Znaki diabetične ketoacidoze (glejte tudi poglavje 2, Opozorila in previdnostni ukrepi) so: - zvišana raven "ketonskih teles" v urinu ali krvi - hitra izguba telesne mase - slabost ali bruhanje - bolečine v trebuhu - prekomerna žeja - hitro in globoko dihanje - zmedenost - neobičajna zaspanost ali utrujenost - sladek vonj izdihanega zraka, sladek ali kovinski okus v ustih ali spremenjen vonj urina ali znoja.
Dapagliflozin: Dapagliflozin was rapidly and well absorbed after oral administration. 
Dapagliflozin: Dapagliflozin se po peroralni uporabi hitro in dobro absorbira.
Qtern 5 mg/10 mg film-coated tablets 
Qtern 5 mg/10 mg filmsko obložene tablete
It is important to continue to follow the advice on diet and exercise given to you by your doctor, pharmacist or nurse. 
Pomembno je, da še naprej upoštevate navodila za dieto in telesno dejavnost, ki vam jih je dal zdravnik, farmacevt ali medicinska sestra.
If pregnancy is detected, treatment with Qtern should be discontinued. 
Če bolnica zanosi, je treba prenehati zdravljenje z zdravilom Qtern.
The mean total systemic clearance of dapagliflozin administered intravenously was 207 ml/min. 
Povprečni skupni sistemski očistek intravensko uporabljenega dapagliflozina je bil 207 ml/min.
Saxagliptin: The Cmax and AUC of saxagliptin and its major metabolite increased proportionally to the saxagliptin dose. 
Saksagliptin: Cmax in AUC saksagliptina in njegovega glavnega presnovka so naraščale sorazmerno z odmerkom saksagliptina.
Mechanism of action for dapagliflozin 
Mehanizem delovanja dapagliflozina
UNIQUE IDENTIFIER 2D BARCODE 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
Rash is also noted as an adverse reaction for this medicinal product (see section 4.8). 
Izpuščaj je zabeležen tudi kot neželen učinek tega zdravila (glejte poglavje 4.8).
The no effect level (NOEL) for the lesions is 1 and 2 times the human exposure of saxagliptin and the major metabolite respectively, at the recommended human dose (RHD) of 5 mg/day. 
Raven brez učinka (NOEL - no effect level) za te spremembe je 1-kratna človeška izpostavljenost saksagliptinu in 2-kratna človeška izpostavljenost njegovemu glavnemu presnovku, dosežena s priporočenim odmerkom za človeka 5 mg/dan.
Subjects at higher risk for hospitalisation for heart failure, irrespective of treatment assignment, could be identified by known risk factors for heart failure such as baseline history of heart failure or impaired renal function. 
Bolnike z večjim tveganjem za sprejem v bolnišnico zaradi srčnega popuščanja je bilo mogoče (ne glede na prejeto zdravljenje) prepoznati po znanih dejavnikih tveganja za srčno popuščanje, npr. po izhodiščni anamnezi srčnega popuščanja ali okvarjenem delovanju ledvic.
Kidney function Your kidneys should be checked before you start taking and whilst you are on this medicine. 
Delovanje ledvic je treba preveriti, preden začnete jemati to zdravilo, in ga preverjati med zdravljenjem.
The coadministration of saxagliptin and CYP3A4/5 inducers, other than rifampicin (such as carbamazepine, dexamethasone, phenobarbital and phenytoin) has not been studied and may result in decreased plasma concentration of saxagliptin and increased concentration of its major metabolite. 
Sočasna uporaba saksagliptina z drugimi induktorji CYP3A4/5 razen rifampicina (npr. s karbamazepinom, deksametazonom, fenobarbitalom in fenitoinom) ni raziskana; povzroči lahko znižanje koncentracije saksagliptina v plazmi in zvišanje koncentracije njegovega glavnega presnovka.